=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Peter Honig, MD, MPH
Pfizer Inc.
NDA 020472/MA 275

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by
facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the
full address above and include a prominent directional notation (e.g. a sticker) to indicate that
the submission is intended for OPDP. Please refer to MA 275 in addition to the NDA number
in all future correspondence relating to this particular matter. All correspondence should
include a subject line that clearly identifies the submission as a Response to Untitled Letter.
OPDP reminds you that only written communications are considered official.

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Estring comply with each
applicable requirement of the FD&C Act and FDA implementing regulations.

Sincerely,

*{See appended electronic signature page}*

Lynn Panholzer, PharmD
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Matthew J. Falter, PharmD
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Page 4

Reference ID: 4280161
